WebDoctor Encyclopedia

Lymphomas

Hepatosplenic T-cell lymphoma

Hepatosplenic T-cell lymphoma is a very rare, aggressive lymphoma of young adults that grows in the spleen, liver and bone marrow rather than lymph nodes. Some cases follow long-term immune-suppressing treatment.

Medically reviewed Last reviewed November 15, 2026

What is hepatosplenic T-cell lymphoma?

Hepatosplenic T-cell lymphoma (HSTCL) is a very rare and aggressive type of non-Hodgkin lymphoma. It starts in a type of T lymphocyte, a white blood cell that is part of the immune system.

Unlike most lymphomas, HSTCL does not usually cause swollen lymph nodes. Instead, the lymphoma cells collect in the spleen, liver and bone marrow. This causes a markedly enlarged spleen and liver and low blood counts.

HSTCL mainly affects teenagers and young adults, especially young men. About one in five people have had a weakened immune system beforehand. This includes people taking certain medicines for inflammatory bowel disease and people who have had an organ transplant (Kotlyar et al., 2011).

Because it is rare and its symptoms are vague, HSTCL is often diagnosed late. Intensive treatment followed by a stem cell transplant offers the best chance of long-term control (Pro, Allen and Behdad, 2020).

1. Key facts at a glance

Feature Details
Type of disease Aggressive peripheral T-cell lymphoma
How common Very rare; about 1-2% of T-cell lymphomas
Typical age Median about 35; most between 15 and 40
Sex Much more common in men
Main sites Spleen, liver and bone marrow
Typical genetic change Isochromosome 7q, often with trisomy 8
Main treatment Intensive chemotherapy, then allogeneic stem cell transplant
Outlook Poor overall; long-term survival is mainly seen after transplant

2. How HSTCL develops

Most T cells carry an alpha-beta T-cell receptor. A small group carry a gamma-delta receptor instead. These gamma-delta T cells normally live in the spleen, gut lining and skin, where they act as a fast first line of defence.

In about three-quarters of cases, HSTCL arises from gamma-delta T cells. In the rest, the cells carry an alpha-beta receptor, but the disease behaves in the same way (Belhadj et al., 2003).

The lymphoma cells have a typical set of genetic changes (McKinney et al., 2017):

Genetic change Approximate frequency Notes
Isochromosome 7q Most cases An abnormal chromosome with two copies of the long arm of chromosome 7
Trisomy 8 Common An extra copy of chromosome 8
SETD2 mutations About a quarter or more Affect the way DNA is packaged
STAT5B and STAT3 mutations About a third Switch on growth signals
PIK3CD mutations Some cases Another growth pathway

3. Causes and risk factors

In most people, the cause is not known. Some groups, however, have a higher risk:

Risk factor Details
Thiopurine medicines Azathioprine or mercaptopurine for inflammatory bowel disease, especially in young men
Thiopurines with anti-TNF drugs Combination therapy with infliximab or adalimumab carries the highest reported risk
Organ transplant Long-term immune-suppressing medicines after a kidney, liver or heart transplant
Other immune problems Some autoimmune diseases and previous cancer treatment

The overall risk is very small, even for people taking these medicines. For most people with inflammatory bowel disease, the benefits of treatment far outweigh this risk.

Doctors are, however, careful about long-term combination therapy in young men. You should never stop a prescribed medicine without talking to your specialist.

HSTCL is not inherited and not infectious.

4. How does it look

Visible signs on the body

HSTCL changes the body in ways that a doctor can often see or feel:

Sign What it looks like
Swollen abdomen A very large spleen, sometimes reaching the pelvis, and a large liver
Pale skin From anaemia
Bruising and small red spots Tiny pinpoint bleeds (petechiae) from low platelets
Weight loss Thin arms and face despite a swollen abdomen
Yellow skin or eyes Jaundice, in some people with liver involvement

Swollen lymph nodes are typically absent. This is an important clue that helps doctors think of HSTCL rather than more common lymphomas.

Under the microscope

The lymphoma cells are medium-sized with a round nucleus and pale cytoplasm. They have a characteristic pattern of spread:

Organ Typical pattern
Spleen Fills the red pulp, the blood-filtering part of the spleen
Liver Lines the small blood channels (sinusoids)
Bone marrow Collects inside the small blood channels, which can be subtle and easy to miss

Cell markers

The cells are usually CD2+, CD3+ and CD7+, but CD4- and CD8- (double negative) and CD5-. Many are CD56+, and they carry the cytotoxic marker TIA-1 (Yabe et al., 2018).

On scans

CT, ultrasound or PET-CT scans show a markedly enlarged spleen and liver. Lymph nodes are usually of normal size.

5. Symptoms

Symptoms often develop over weeks to a few months. They can be mistaken for an infection or for a flare of another illness.

Common symptoms

  • Fever, often lasting for weeks without an obvious infection
  • Drenching night sweats
  • Unintended weight loss
  • Tiredness, weakness and breathlessness, from anaemia
  • Pain or fullness in the upper left abdomen, from the enlarged spleen
  • Feeling full after small meals
  • Easy bruising, nosebleeds or bleeding gums, from low platelets
  • Frequent infections, from low neutrophils

Haemophagocytic lymphohistiocytosis

Some people develop haemophagocytic lymphohistiocytosis (HLH). This is a dangerous over-activation of the immune system, which causes high fever, very low blood counts, liver problems and sometimes confusion. It needs urgent specialist treatment.

When to seek medical advice

See a doctor promptly if you have fever without an obvious cause, night sweats, weight loss, abdominal swelling or easy bruising.

If you take a thiopurine or anti-TNF medicine and develop these symptoms, tell your specialist team quickly.

6. Diagnosis

Test Purpose
Full blood count and blood film Low platelets are very common; anaemia and low white cells may also be seen
Liver function tests and LDH Liver involvement and disease activity
Bone marrow biopsy Usually involved; special stains show cells in the marrow sinusoids
Flow cytometry Identifies the T-cell type and the gamma-delta receptor
Chromosome tests (FISH) Look for isochromosome 7q and trisomy 8
Liver biopsy or splenectomy When the marrow does not give a clear answer
PET-CT scan Shows the extent of disease
Tests for EBV, HLH and infections Exclude other causes of fever and low counts

Conditions that can look similar

Condition How it differs
T-cell LGL leukaemia (gamma-delta type) Usually slow-growing; different pattern in marrow and spleen
Other gamma-delta T-cell lymphomas Often affect the skin or gut instead
Aggressive NK-cell leukaemia Linked with Epstein-Barr virus; usually in Asia
Infections such as leishmaniasis or tuberculosis Can cause a large spleen, fever and low counts

7. Treatment

HSTCL should be treated at a specialist lymphoma centre with access to stem cell transplantation. Because the disease is rare, clinical trials are strongly encouraged.

Stopping immune-suppressing medicines

If HSTCL develops while a person is taking immune-suppressing medicines, these are reduced or stopped where possible. Specialists plan alternative treatment for the underlying condition.

First treatment

Standard CHOP chemotherapy, which is used for many other lymphomas, gives poor results in HSTCL. Specialists usually recommend more intensive regimens (Klebaner et al., 2020):

Regimen Main drugs
ICE Ifosfamide, carboplatin, etoposide
IVAC Ifosfamide, etoposide, high-dose cytarabine
Hyper-CVAD Several drugs given in alternating cycles
CHOEP or EPOCH Options for people who cannot have more intensive treatment

Treatment is given in hospital. It can cause low blood counts, infections, sickness, hair loss and tiredness, so supportive care is an important part of the plan.

Stem cell transplant

The best results are seen when people who respond to chemotherapy go on to have an allogeneic stem cell transplant (from a donor) in first remission (Rashidi et al., 2015).

A donor search usually starts soon after diagnosis. This is because the time window can be short.

Transplant step What happens
Conditioning High-dose chemotherapy, sometimes with radiotherapy
Infusion Donor stem cells are given through a drip
Engraftment New blood cells start to grow, usually in 2-4 weeks
Recovery Several months, with close monitoring for infections and graft-versus-host disease

Other treatments

Treatment When it is used
Splenectomy Sometimes for diagnosis or to improve low platelets
Alemtuzumab, pentostatin, romidepsin, pralatrexate Reported in some patients, mainly at relapse
Targeted drugs Under study, including JAK and PI3K inhibitors
HLH treatment Steroids, etoposide and supportive care if HLH develops

8. Outlook (prognosis)

HSTCL is one of the most serious lymphomas. Historically, median survival has been about 1-2 years (Belhadj et al., 2003; Foss et al., 2020).

Outcomes are better for people who reach complete remission and have an allogeneic transplant. In this group, a proportion remain well for many years.

Factor Effect
Complete remission after induction Better outlook
Allogeneic transplant in first remission Best chance of long-term survival
Intensive non-CHOP induction Better responses than CHOP
Alpha-beta type, older age, poor fitness May be linked with poorer outcomes
Refractory or relapsed disease Difficult to treat

If you have inflammatory bowel disease

If you take azathioprine, mercaptopurine or an anti-TNF medicine, your specialist will have weighed the benefits and risks carefully. HSTCL is extremely rare, even in this group.

Routine blood tests during treatment can sometimes pick up early warning signs, such as a falling platelet count or abnormal liver tests. Tell your team about unexplained fever, sweats, weight loss or a swollen abdomen, and do not stop any medicine without advice.

Recovery after transplant

Stage What to expect
First 100 days Frequent clinic visits, blood tests and medicines to prevent infection and graft-versus-host disease
First year Gradual return of energy; vaccinations are repeated; some immune-suppressing medicines are reduced
Long term Yearly checks of heart, lungs, hormones, bones and skin; screening for late effects and second cancers

Many people return to study or work within a year of transplant, though recovery varies widely.

9. Living with HSTCL

Being diagnosed with a rare, aggressive lymphoma is very hard, especially for young people and their families. Support is available from specialist nurses, psychologists and lymphoma charities.

  • Ask about fertility preservation before starting chemotherapy
  • Know the signs of infection, and seek help immediately for fever
  • Arrange practical support for work, study and finances
  • Look after your mental health, and ask for counselling if needed
  • Keep a single contact number for your treatment team
  • Bring a relative or friend to important appointments to help remember information

10. Frequently asked questions

Question Answer
Was my bowel medicine the cause? It may have contributed, but most people who take these medicines never develop HSTCL
Why are my lymph nodes not swollen? HSTCL typically involves the spleen, liver and marrow rather than lymph nodes
Can HSTCL be cured? Long-term remission is possible, mainly after a donor stem cell transplant
Is it inherited? No
Will I need my spleen removed? Not always; splenectomy is sometimes used to confirm the diagnosis or to improve very low platelet counts
How long does treatment take? Chemotherapy usually takes 3-4 months, followed by transplant and several months of recovery
Can my family be donors? Brothers and sisters are tested first; unrelated or half-matched donors are also used

11. Questions to ask your care team

  • Is my lymphoma the gamma-delta or alpha-beta type?
  • Which chemotherapy do you recommend, and why?
  • When should we start a donor search?
  • What should I do about my other medicines?
  • Can I preserve my fertility before treatment?
  • Are there clinical trials I can join?

Resources

  1. Pro, B., Allen, P. and Behdad, A. (2020) ‘Hepatosplenic T-cell lymphoma: a rare but challenging entity’, Blood, 136(18), pp. 2018-2026.
  2. Belhadj, K. et al. (2003) ‘Hepatosplenic gammadelta T-cell lymphoma is a rare clinicopathologic entity with poor outcome: report on a series of 21 patients’, Blood, 102(13), pp. 4261-4269.
  3. McKinney, M. et al. (2017) ‘The genetic basis of hepatosplenic T-cell lymphoma’, Cancer Discovery, 7(4), pp. 369-379.
  4. Kotlyar, D.S. et al. (2011) ‘A systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease’, Clinical Gastroenterology and Hepatology, 9(1), pp. 36-41.
  5. Klebaner, D. et al. (2020) ‘Intensive induction therapy compared with CHOP for hepatosplenic T-cell lymphoma’, Clinical Lymphoma, Myeloma and Leukemia, 20(7), pp. 431-437.
  6. Rashidi, A. et al. (2015) ‘Outcomes of allogeneic stem cell transplantation in hepatosplenic T-cell lymphoma’, Blood Cancer Journal, 5(6), p. e318.
  7. Foss, F.M. et al. (2020) ‘Incidence and outcomes of rare T cell lymphomas from the T Cell Project: hepatosplenic, enteropathy associated and peripheral gamma delta T cell lymphomas’, American Journal of Hematology, 95(2), pp. 151-155.
  8. Yabe, M. et al. (2018) ‘Hepatosplenic T-cell lymphoma: a review of clinicopathologic features, pathogenesis, and prognostic factors’, Human Pathology, 74, pp. 5-16.
  9. Alaggio, R. et al. (2022) ‘The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: lymphoid neoplasms’, Leukemia, 36(7), pp. 1720-1748.
  10. National Cancer Institute (2026) Adult Non-Hodgkin Lymphoma Treatment (PDQ) – Health Professional Version. Available at: https://www.cancer.gov/types/lymphoma/hp/adult-nhl-treatment-pdq (Accessed: October 2026).

Prepared by the editorial team, October 2026.